NYSE$AGL
agilon health inc. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
agilon health's Q2 2024 results were reported, showing revenue increase and maintained medical margin and Adjusted EBITDA guidance.
agilon health reported a 39% increase in revenue to $1.48 billion for Q2 2024. The company is maintaining its medical margin and Adjusted EBITDA guidance for the full year.
- Total members on the agilon platform increased to 645,000 as of June 30, 2024, including 513,000 Medicare Advantage members and 132,000 ACO model beneficiaries.
- Medicare Advantage membership increased 38%, with 6% growth in same partner geographies.
- Total revenue of $1.48 billion in the second quarter 2024 increased 39% compared to $1.07 billion in the second quarter 2023.
- Net loss was $31 million in the second quarter 2024 compared to $17 million in the second quarter 2023.
Headline financials
Revenue & EPS history
agilon health · Revenue · Quarterly
$1.48B
Revenue by segment
agilon health · $1.15B total across 2 segments · Q2 2023
- Medical Services Revenue$1.15B+71.4%99.8%
- Other Operating Revenue$2.01M+111.4%0.2%
Forward guidance
agilon health maintains its 2024 Medical Margin and Adjusted EBITDA Guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-2.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+6.7%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+20.2%
Q4 2025
Best reaction
-36.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +122.0% | +256.9% | |
| Q4 2025 | +20.2% | +13.4% | -20.8% | |
| Q3 2025 | +5.1% | -9.0% | -9.9% | |
| Q1 2025 | -25.6% | -33.4% | -51.6% | |
| Q4 2024 | -7.4% | -17.9% | +23.7% | |
| Q3 2024 | -36.1% | -35.1% | -24.7% | |
| Q2 2024 | -12.7% | -14.6% | -36.8% | |
| Q1 2024 | +7.5% | +7.5% | +40.8% | |
| Q4 2023 | +3.1% | -2.1% | -1.1% | |
| Q3 2023 | -13.1% | -19.0% | -33.1% | |
| Q2 2023 | +0.7% | +3.7% | -7.9% | |
| Q1 2023 | -3.4% | -6.6% | -18.9% | |
| Q4 2022 | +15.4% | +14.8% | +12.0% | |
| Q3 2022 | -12.7% | -7.9% | -8.6% | |
| Q2 2022 | -3.3% | -0.4% | -20.3% | |
| Q1 2022 | -8.6% | -19.4% | +1.3% | |
| Q4 2021 | +10.6% | +2.4% | +31.7% | |
| Q3 2021 | +2.7% | +3.6% | -9.5% | |
| Q2 2021 | -3.8% | -6.3% | -3.4% | |
| Q1 2021 | +6.3% | +4.0% | +14.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro